Notice of Interim Results

RNS Number : 8846J
Oxford Biomedica PLC
23 July 2013
 

 

 

 

 

 

 

Oxford BioMedica: Notice of Interim Results

Results date: 29 August 2013

 

 

Oxford, UK - 23 July 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2013 on Thursday, 29 August 2013.

 

An analyst briefing will be held at 09:30am GMT on Thursday, 29 August 2013 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.  An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk.

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

Lara Mott, Head of Investor Relations and Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/Matthew Neal

M:Communications

 

 

Tel: +44 (0)20 7920 2345

 

Notes to editors

 

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NORDLLFLXDFBBBX